Tackling the Challenges in the Vascular and Endovascular Arena
Total Page:16
File Type:pdf, Size:1020Kb
CHARING CROSS SPECIAL EDITION March 2016 2016 Vascular & Endovascular Challenges Update Tackling the challenges in the vascular and endovascular arena Peripheral Acute Aortic Venous Arterial Stroke Challenges Challenges Challenges Challenges Halfway through its Controversies, Challenges and Consensus allow the audience to interact with the Challenges Programme—new as of cycle, the Charing Cross Symposium will examine this year the speakers and panel at every stage. 2016—will make its debut. The half-day numerous and varied challenges currently facing the vascular This year, the CX Venous Challenges Programme is being introduced following and endovascular field. The Symposium will be held from 26 to 29 Main Programme will, for the first time, the realisation that a number of strokes April 2016 at Olympia Grand, London, UK. take place on the Symposium’s opening are caused by interventions in the aorta day, exploring the use of various technolo- and manipulations in the arch. his year’s Peripheral Arterial aortic aneurysm trial to be conducted, gies and techniques for the treatment of The purpose of the Acute Stroke Chal- Challenges session will centre and the first to reach fifteen-year follow- superficial and deep venous disease with lenges Main Programme is to encourage around management of the up. The 10-year data, presented at CX emphasis on the latest evidence of when a multidisciplinary approach, such that superficialT femoral artery. Treatment 2010, demonstrated no significant dif- and in which patients they should be used. unwanted emboli to the brain can be man- strategies, varying depending on lesion ferences between endovascular and open The topics for discussion will include aged by clot retrieval, and the optimisation type and length, will be analysed, with repair in terms of mortality. acute deep vein thrombosis and deep vein of referral so that stroke patients reach the a special emphasis on the status and Another first-time presentation in the stenting challenges, proximal deep venous best hands as fast as possible. expectations of drug-coated balloons, Abdominal Aortic Main Programme will obstruction and pelvic vein reflux chal- The new CX Vascular Access drug-eluting stents, new biomimetic and be an Individual Patient Data meta- lenges. A new session on lymphoedema Course will be held on the second, third swirling flow stents and stent grafts. analysis of the EVAR vs. open repair challenges will precede discussions on and fourth days of the Symposium. The Delegates will be able to learn new randomised controlled trials—EVAR 1, superficial venous challenges. Course will provide both experts and those techniques for femoropopliteal lesion DREAM, OVER and ACE. The ever-popular CX Venous new to the field with invaluable insights treatment through attending the CX On the third day, the Main Programme Workshop will run throughout days into the challenges currently facing haemo- Peripheral Arterial Live Cases, which will be dedicated to challenges in the two and three, consisting of one-to-one dialysis vascular access, and the methods returns after its successful 2015 debut. treatment of thoracic aortic diseases, with demonstrations by world-leading experts. used to overcome them. The three-day This year’s live cases will be broadcast an emphasis on type B dissections. The Workshop will expand on the Course will bring together world experts to from Münster, Germany. Also on the third day, the CX Aortic Ed- technical aspects of the key superficial cover current practice and remaining chal- The main talking point of the 2016 Ab- ited Cases will explore the application of and deep venous topics discussed in the lenges. It will be made up of a masterclass dominal Aortic Challenges session is the different techniques in complex thoracic CX Venous Main Programme. This year, on ischaemic steal syndrome, a practical presentation—for the first time—of15- aortic and abdominal aortic procedures. a new section on aesthetic phlebology skills course and an abstract presentation year follow-up data from the Endovas- The format will be that of short case will also be included in the workshop. day, immersing delegates in the most im- cular Aneurysm Repair (EVAR) 1 Trial, presentations followed by imaging and On the final day of this year’s portant issues and innovation in haemodi- the first EVAR vs. open repair abdominal indications for the procedure, and will Symposium, the Acute Stroke alysis vascular access medicine. VascularNews.com Facebook.com/VascularNews @VascularNews VN App 2 Charing Cross Symposium March 2016 Management of the superficial femoral artery Delegates to learn techniques for femoropopliteal at the centre of the discussions at CX lesions with the CX live-case method 26 APRIL 2016 topics are related 27 APRIL 2016 edited cases will Day UPPER MAIN to the outcome Day LOWER MAIN also be presented. AUDITORIUM of drug-eluting AUDITORIUM “Our main aim is 1 technologies in 2 to provide highly The management of peripheral inter- Following the successful educational cases. the superficial femoral artery will be at ventions. More first year of the CX Peripheral Arterial During the session, the centre of the discussions at the CX than 20 years after Live Cases, CX 2016 will continue to we will discuss Peripheral Arterial Challenges Day of the establishing drug- Thomas Zeller offer delegates the opportunity to expand indications and Charing Cross Symposium 2016 (Tuesday eluting stents as the discussion of key topics from the CX reasons for us- Giovanni Torsello 26 April). Treatment strategies, depending a first-line strategy in coronary interven- Peripheral Arterial Main Programme by ing a particular on lesion type and length, will be analysed tions, drug-eluting stents and drug-coated demonstrating techniques of how device, we will present specific fea- and there will be special emphasis on balloons are becoming estab- to achieve best results in tures and characteristics of the materi- the status and expectations with different lished for femoropopliteal femoropopliteal le- als and we will demonstrate technical modalities: drug-coated balloons, drug- interventions. Drug- sions through the CX tips and tricks to ensure a safe and eluting stents, new stents (swirling flow coated balloons are live-case method. effective intervention,” said Bisdas. and biomimetic stents) and stent grafts. attractive alternatives This year, live The cases will be divided into two There is high expectation of what can to stent based (bare cases will be different parts. In the first part, differ- be achieved by drug-coated balloons, yet metal and drug- Peripheral transmitted ent techniques supporting the concept there is healthy scepticism on how durable eluting) treatment from Münster, of “leaving nothing behind” will be they will be for longer lesions. “It may take strategies, at least in Arterial Germany, with demonstrated. These include drug-coated two to three years before we know for sure less severe calcified Arne Schwindt balloons in challenging long occlusions, how the drug-coated balloon compares lesions, whereas Challenges and Theodosios atherectomy and scoring balloons. In with stents particularly for longer lesions,” drug-eluting stents Bisdas as main the second part, the concept of “leaving says Roger Greenhalgh, chairman of the show beneficial clinical operators. Giovanni something in” will be presented. During CX Programme Organising Board. long-term results over Torsello, Thomas these cases, the delegates will have the He continues, “Stents are used more bare metal stents. Interest- Zeller, Iris Baumgartner opportunity to view the deployment of commonly for longer lesions and better ing presentations will include and Michael Jaff will lead drug-eluting stents, biomimetic stents and results are sought by engaging swirl- analyses of specific restenosis patterns audience participation in London stent grafts. Finally, a case of percutane- ing flow or stents with strong radial following drug-eluting stent angioplasty. and try to shed light on why a technique ous transluminal rotational thrombectomy strength. Data on these technologies will is chosen for a particular situation. Some will be presented. be discussed. Additionally, the value of What do you think are the drug-eluting stents has been demonstrated biggest challenges physi- with five-year data and now newer scaf- cians are facing treating CX ilegx Collaboration Day addresses folds are available. All current options will peripheral arterial disease? be explored at Charing Cross 2016.” In general the biggest challenge in proactive approach to treating the diabetic foot Data on other technologies (atherectomy, some countries is that new and effec- sequential stents and single long stents), tive technologies such as drug-coated 28 APRIL 2016 which are being used in the treatment of balloons and drug-eluting stents are Day PILLAR HALL LEARNING CENTRE long lesions, will also be discussed. not adequately reimbursed, and this Delegates at CX 2016 will also hear new limits their more liberal clinical use 3 With the aim of promoting endovascular procedures, open vascular data on the IN.PACT drug-coated balloon withholding effective treatment op- the best possible care of the surgery, urgent surgical debridement and two-year results in women and diabetics, tions for a large number of patients. ischaemic lower limb to reduce the num- aggressive treatment of infection. The data from IN.PACT Global in total occlu- The most relevant technical challenge ber of major amputations, the CX